Impact of Age and Comorbidity on Treatment and Outcomes in Elderly Cancer Patients

Seminars in Radiation Oncology

Volumn 22, Issue 4, 2012, Pages 265-271

  Chen, Ronald C ^a,b   Royce, Trevor J ^a   Extermann, Martine ^c,d   Reeve, Bryce B ^b,e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; HORMONE; NAVELBINE;

ACUTE TOXICITY; ADVANCED CANCER; AGE; AGED; BLADDER CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHARLSON ROMANO COMORBIDITY SCORE; CLINICAL TRIAL (TOPIC); COLON CANCER; COMORBIDITY; CYSTECTOMY; DRUG FATALITY; DYSPNEA; ENDOMETRIUM CANCER; ESOPHAGITIS; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GERIATRIC ASSESSMENT; GERIATRIC PATIENT; GROUPS BY AGE; HEAD AND NECK CANCER; HEMATOLOGIC DISEASE; HUMAN; KLABUNDE COMORBIDITY SCORE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDICARE; META ANALYSIS (TOPIC); MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; NEUTROPENIA; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT MONITORING; PHYSICIAN; PNEUMONIA; POSTOPERATIVE CARE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; RECTUM HEMORRHAGE; REVIEW; SCORING SYSTEM; SEXUAL FUNCTION; SOLID TUMOR; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIA; TREATMENT OUTCOME; UNITED STATES; WEAKNESS;

AGE FACTORS; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DECISION MAKING; EVIDENCE-BASED MEDICINE; GERIATRIC ASSESSMENT; HUMANS; NEOPLASMS; PATIENT SELECTION; PREVALENCE; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 84866315162     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2012.05.002     Document Type: Review

References (89)

1. Mell L.K., Mundt A.J. Radiation therapy in the elderly. Cancer J 2005, 11:495-505.
2. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Edwards B.K., Howe H.L., Ries L.A., et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002, 94:2766-2792.
4. Cooperberg M.R., Broering J.M., Carroll P.R. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010, 28:1117-1123.
5. Miller D.C., Gruber S.B., Hollenbeck B.K., et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006, 98:1134-1141.
6. Hamilton A.S., Albertsen P.C., Johnson T.K., et al. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int 2011, 107:576-584.
7. Holmes J., Wang Z.A., Hoffman K.E., et al. Is primary prostate cancer treatment influenced by likelihood of extraprostatic disease?. A patterns of care study using the surveillance epidemiology and end results database. Int J Radiat Biol Phys 2012 Jan 31, [Epub ahead of print].
8. Fedeli U., Fedewa S.A., Ward E.M. Treatment of muscle invasive bladder cancer: Evidence from the national cancer database, 2003 to 2007. J Urol 2011, 185:72-78.
9. Snyder C., Harlan L., Knopf K., et al. Patterns of care for the treatment of bladder cancer. J Urol 2003, 169:1697-1701.
10. Owonikoko T.K., Ragin C.C., Belani C.P., et al. Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007, 25:5570-5577.
11. McMahon M., Barbiere J.M., Greenberg D.C., et al. Population-based trends in use of surgery for non-small cell lung cancer in a UK region, 1995-2006. Thorax 2011, 66:453-455.
12. Louwman W.J., Janssen-Heijnen M.L., Houterman S., et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: A population-based study. Eur J Cancer 2005, 41:779-785.
13. Yancik R. Cancer burden in the aged: An epidemiologic and demographic overview. Cancer 1997, 80:1273-1283.
14. Hewitt M., Rowland J.H., Yancik R. Cancer survivors in the United States: Age, health, and disability. J Gerontol A Biol Sci Med Sci 2003, 58:82-91.
15. Smith A.W., Reeve B.B., Bellizzi K.M., et al. Cancer, comorbidities, and health-related quality of life of older adults. Health Care Financ Rev 2008, 29:41-56.
16. Schrag D., Cramer L.D., Bach P.B., et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001, 93:850-857.
17. Samet J., Hunt W.C., Key C., et al. Choice of cancer therapy varies with age of patient. JAMA 1986, 255:3385-3390.
18. O'Connell J.B., Maggard M.A., Ko C.Y. Cancer-directed surgery for localized disease: Decreased use in the elderly. Ann Surg Oncol 2004, 11:962-969.
19. Goodwin J.S., Hunt W.C., Samet J.M. Determinants of cancer therapy in elderly patients. Cancer 1993, 72:594-601.
20. Guadagnoli E., Weitberg A., Mor V., et al. The influence of patient age on the diagnosis and treatment of lung and colorectal cancer. Arch Intern Med 1990, 150:1485-1490.
21. Chen R.C., Bainbridge K., Carpenter W.R., et al. Racial differences in receipt of guideline-recommended treatment in men with low-, intermediate-, and high-risk prostate cancer (CaP): A population-based study. J Clin Oncol 2010, 28(15s). (suppl; abstr 9002).
22. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
23. Yancik R., Wesley M.N., Ries L.A., et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001, 285:885-892.
24. Schonberg M.A., Marcantonio E.R., Li D., et al. Breast cancer among the oldest old: Tumor characteristics, treatment choices, and survival. J Clin Oncol 2010, 28:2038-2045.
25. Mandelblatt J.S., Hadley J., Kerner J.F., et al. Patterns of breast carcinoma treatment in older women: Patient preference and clinical and physical influences. Cancer 2000, 89:561-573.
26. Newcomb P.A., Carbone P.P. Cancer treatment and age: Patient perspectives. J Natl Cancer Inst 1993, 85:1580-1584.
27. Bergman L., Decker G., van Leeuwen F.E., et al. The effect of age on treatment choice and survival in elderly breast cancer patients. Cancer 1991, 67:2227-2234.
28. Bergman L., Kluck H.M., van Leeuwen F.E., et al. The influence of age on treatment choice and survival of elderly breast cancer patients in south-eastern Netherlands: A population-based study. Eur J Cancer 1992, 28A:1475-1480.
29. Hurria A., Leung D., Trainor K., et al. Factors influencing treatment patterns of breast cancer patients age 75 and older. Crit Rev Oncol Hematol 2003, 46:121-126.
30. Mor V., Masterson-Allen S., Goldberg R.J., et al. Relationship between age at diagnosis and treatments received by cancer patients. J Am Geriatr Soc 1985, 33:585-589.
31. Silliman R.A., Guadagnoli E., Weitberg A.B., et al. Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol 1989, 44:M46-M50.
32. Ring A., Sestak I., Baum M., et al. Influence of comorbidities and age on risk of death without recurrence: A retrospective analysis of the Arimidex, tamoxifen alone or in combination trial. J Clin Oncol 2011, 29:4266-4272.
33. Chu J., Diehr P., Feigl P., et al. The effect of age on the care of women with breast cancer in community hospitals. J Gerontol 1987, 42:185-190.
34. Greenfield S., Blanco D.M., Elashoff R.M., et al. Patterns of care related to age of breast cancer patients. JAMA 1987, 257:2766-2770.
35. Lavelle K., Todd C., Moran A., et al. Non-standard management of breast cancer increases with age in the UK: A population based cohort of women > or = 65 years. Br J Cancer 2007, 96:1197-1203.
36. Mustacchi G., Cazzaniga M.E., Pronzato P., et al. Breast cancer in elderly women: A different reality?. Results from the NORA study. Ann Oncol 2007, 18:991-996.
37. Ayanian J.Z., Zaslavasky A.M., Fuchs C.S., et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol 2003, 21:1293-1300.
38. Huang S.H., O'Sullivan B., Waldron J., et al. Patterns of care in elderly head-and-neck cancer radiation oncology patients: A single-center cohort study. Int J Radiat Oncol Biol Phys 2011, 79:46-51.
39. Truong P.T., Kader H.A., Lacy B., et al. The effects of age and comorbidity on treatment and outcomes in women with endometrial cancer. Am J Clin Oncol 2005, 28:157-164.
40. Gore J.L., Litwin M.S., Lai J., et al. Use of radical cystectomy for patients with invasive bladder cancer. J Natl Cancer Inst 2010, 102:802-811.
41. Audisio R.A., Ramesh H., Longo W.E., et al. Preoperative assessment of surgical risk in oncogeriatric patients. Oncologist 2005, 10:262-268.
42. Bouchardy C., Rapiti E., Fioretta G., et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 2003, 21:3580-3587.
43. Frasci G., Lorusso V., Panza N., et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000, 18:2529-2536.
44. Widmark A., Klepp O., Solberg A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial. Lancet 2009, 373:301-308.
45. Zietman A.L., Bae K., Slater J.D., et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from proton radiation oncology group/American College of Radiology 95-09. J Clin Oncol 2010, 28:1106-1111.
46. Kuban D.A., Tucket S.L., Dong L., et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
47. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24:1990-1996.
48. D'Amico A.V., Chen M.H., Renshaw A.A., et al. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 2008, 299:289-295.
49. Jones C.U., Hunt D., McGowan D.G., et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011, 365:107-118.
50. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002, 360:103-106.
51. Bolla M., de Reijke T.M., Van Tienhoven G., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527.
52. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26:2497-2504.
53. Shipley W.U., Winter K.A., Kaufman D.S., et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of radiation therapy Oncology Group 89-03. J Clin Oncol 1998, 16:3576-3583.
54. Kaufman D.S., Winter K.A., Shipley W.U., et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 2009, 73:833-837.
55. Rödel C., Grabenbauer G.G., Kühn R., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 2002, 20:3061-3071.
56. Efstathiou J.A., Spiegel D.Y., Shipley W.U., et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience. Eur Urol 2011, 61:705-711.
57. Zehnder P., Studer U.E., Skinner E.C., et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: A comparative study. J Urol 2011, 186:1261-1268.
58. Muss H.B., Woolf S., Berry D., et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005, 293:1073-1081.
59. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005, 366:2087-2106.
60. Hutchins L.F., Unger J.M., Crowley J.J., et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 341:2061-2067.
61. Trimble E.L., Carter C.L., Cain D., et al. Representation of older patients in cancer treatment trials. Cancer 1994, 74(7 suppl):2208-2214.
62. Benson A.B., Pregler J.P., Bean J.A., et al. Oncologists' reluctance to accrue patients onto clinical trials: An Illinois Cancer Center study. J Clin Oncol 1991, 9:2067-2075.
63. Yee K.W., Pater J.L., Pho L., et al. Enrollment of older patients in cancer treatment trials in Canada: Why is age a barrier?. J Clin Oncol 2003, 21:1618-1623.
64. Kemeny M.M., Peterson B.L., Kornblith A.B., et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003, 21:2268-2275.
65. Pignon T., Gregor A., Schaake Koning C., et al. Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother Oncol 1998, 46:239-248.
66. Rocha Lima C.M., Herndon J.E., Kosty M., et al. Therapy choices among older patients with lung carcinoma: An evaluation of two trials of the cancer and Leukemia Group B. Cancer 2002, 94:181-187.
67. Schild S.E., Stella P.J., Geyer S.M., et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 2003, 21:3201-3206.
68. Jani A.B., Parikh S.D., Vijayakumar S., et al. Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer. Urology 2005, 65:1157-1162.
69. Skwarchuk M.W., Jackson A., Zelefsky M.J., et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 2000, 47:103-113.
70. Gulley J.L., Figg W.D., Steinberg S.M., et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 2005, 173:1567-1571.
71. Gulley J.L., Aragon-Ching J.B., Steinberg S.M., et al. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2008, 180:1432-1437.
72. Pickles T., Agranovich A., Berthelet E., et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 2002, 94:362-367.
73. Yoon F.H., Gardner S.L., Danjoux C., et al. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. J Urol 2008, 180:1438-1443.
74. Grønberg B.H., Sundstrøm S., Kaasa S., et al. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer 2010, 46:2225-2234.
75. Lee L., Cheung W.Y., Atkinson E., et al. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: A systematic review. J Clin Oncol 2011, 29:106-117.
76. Giordano S.H., Lee A., Kuo Y.F., et al. Late gastrointestinal toxicity after radiation for prostate cancer. Cancer 2006, 107:423-432.
77. Budäus L., Bolla M., Bossi A., et al. Functional outcomes and complications following radiation therapy for prostate cancer: A critical analysis of the literature. Eur Urol 2012, 61:112-127.
78. Bruner D.W., Bryan C.J., Aaronson N., et al. Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol 2007, 25:5051-5057.
79. Wagner L.I., Wenzel L., Shaw E., et al. Patient-reported outcomes in phase II cancer clinical trials: Lessons learned and future directions. J Clin Oncol 2007, 25:5058-5062.
80. Wedding U., Röhrig B., Klippstein A., et al. Co-morbidity and functional deficits independently contribute to quality of life before chemotherapy in elderly cancer patients. Support Care Cancer 2007, 15:1097-1104.
81. Sprangers M.A., de Regt E.B., Andries F., et al. Which chronic conditions are associated with better or poorer quality of life?. J Clin Epidemiol 2000, 53:895-907.
82. Sloan J.A., Cella D., Frost M., et al. Assessing clinical significance in measuring oncology patient quality of life: Introduction to the symposium, content overview, and definition of terms. Mayo Clin Proc 2002, 77:367-370.
83. Overcash J., Extermann M., Parr J., et al. Validity and reliability of the FACT-G scale for use in the older person with cancer. Am J Clin Oncol 2001, 24:591-596.
84. Oozeer N.B., Benbow J., Downs C., et al. The effect of comorbidity on quality of life during radiotherapy in head and neck cancer. Otolaryngol Head Neck Surg 2008, 139:268-272.
85. Daskivich T.J., van de Poll-Franse Kwan L., et al. From bad to worse: Comorbidity severity and quality of life after treatment for early-stage prostate cancer. Prostate Cancer Prostatic Dis 2010, 13:320-327.
86. Chen R.C., Clark J.A., Manola J., et al. Treatment "mismatch" in early prostate cancer: Do treatment choices take patient quality of life into account?. Cancer 2008, 112:61-68.
87. Hu J.C., Elkin E.P., Pasta D.J., et al. Predicting quality of life after radical prostatectomy: Results from CaPSURE. J Urol 2004, 171:703-707.
88. Hurria A., Togawa K., Mohile S.G., et al. Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 2011, 29:3457-3465.
89. Extermann M., Boler I., Reich R.R., et al. Predicting the risk of chemotherapy toxicity in older patients: The chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer 2012, 118(13):3377-3386.